Management of coumarin-associated coagulopathy in the non-bleeding patient: A systematic review

Haematologica

Volumn 89, Issue 7, 2004, Pages 857-862

  Dentali, Francesco ^a   Ageno, Walter ^a,b  

^a UNIVERSITY OF INSUBRIA   (Italy)

^b OSPEDALE DI CIRCOLO   (Italy)

Author keywords

Acenocoumarol; Coagulopathy; Vitamin K; Warfarin

Indexed keywords

ACENOCOUMAROL; ANTICOAGULANT AGENT; PHYTOMENADIONE; WARFARIN;

ANAPHYLAXIS; ANTICOAGULANT THERAPY; BLEEDING; BLOOD CLOTTING DISORDER; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG HYPERSENSITIVITY; HUMAN; INTERNATIONAL STANDARD UNIT; LOW DRUG DOSE; REVIEW; RISK ASSESSMENT; SKIN MANIFESTATION; SYSTEMATIC REVIEW; TREATMENT WITHDRAWAL;

ANTICOAGULANTS; ANTIFIBRINOLYTIC AGENTS; BLOOD COAGULATION DISORDERS; COSTS AND COST ANALYSIS; COUMARINS; HEMORRHAGE; HUMANS; INTERNATIONAL NORMALIZED RATIO; RISK FACTORS; VITAMIN K; WARFARIN; WITHHOLDING TREATMENT;

EID: 3242793451     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (27)

1. Hull R, Hirsh J, Jay R, Carter C, England C, Gent M, et al. Different intensities of oral anticoagulant therapy in the treatment of proximal-vein thrombosis. N Engl J Med 1982;307:1676-81.
2. Landefeld CS, Beyth RJ. Anticoagulant-related bleeding: clinical epidemiology, prediction, and prevention. Am J Med 1993;95:315-28.
3. Fihn SD, Callahan CM, Martin DC, McDonell MB, Henikoff JG, White RH. The risk for and severity of bleeding complications in elderly patients treated with warfarin. The National Consortium of Anticoagulation. Ann Intern Med 1996;124:970-9
4. Oden A, Fahlen M. Oral anticoagulation and risk of death: a medical record linkage study. Br Med J 2002;325:1073-5.
5. Hylek EM, Chang YC, Skates SJ, Hughes RA, Singer DE. Prospective study of the outcomes of ambulatory patients with excessive warfarin anticoagulation. Arch Intern Med 2000;160:1612-7.
6. Ansell J, Hirsh J, Dalen J, Bussey H, Anderson D, Poller L, et al. Managing oral anticoagulant therapy. Chest 2001;119:22S-38S
7. Wilson SE, Douketis JD, Crowther MA. Treatment of warfarin-associated coagulopathy: a physician survey. Chest 2001;120:1972-6.
8. Libby EN, Garcia DA. A survey of oral vitamin K use by anticoagulation clinics. Arch Intern Med 2002;162:1893-6.
9. Glover JJ, Morrill GB. Conservative treatment of overanticoagulated patients. Chest 1995;108:987-90.
10. Lousberg TR, Witt DM, Beall DG, Carter BL, Malone DC. Evaluation of excessive anticoagulation in a group model health maintenance organization. Arch Intern Med 1998;158:528-34.
11. Shetty HGM, Backhouse G, Bentley DP, Routledge PA. Effective reversal of warfarin-induced excessive anticoagulation with low dose vitamin K1. Thromb Haemost 1992;67:13-5.
12. Hung A, Singh S, Tait RC. A prospective randomized study to determine the optimal dose of intravenous vitamin K in reversal of over-warfarinization. Br J Haematol 2000;109:537-9.
13. Andersen P, Godal HC. Predictable reduction in anticoagulant activity of warfarin by small amounts of vitamin K. Acta Med Scand 1975;198:269-70.
14. Byrd DC, Stephens MA, Hamann GL, Dorko C. Subcutaneous phytonadione for reversal of warfarin-induced elevation of the International Normalized Ratio. Am J Health Syst Pharm 1999;56:2312-5.
15. Nee R, Doppenschmidt D, Donovan DJ, Andrews TC. Intravenous versus subcutaneous vitamin K1 in reversing excessive oral anticoagulation. Am J Cardiol 1999;83:286-8.
16. Raj G, Kumar R, McKinney WP. Time course of reversal of anticoagulant effect of warfarin by intravenous and subcutaneous phytonadione. Arch Intern Med 1999;159:2721-4.
17. Crowther MA, Douketis JD, Schnurr T, Steidl L, Mera V, Ultori C, et al. Oral vitamin K is more effective than subcutaneous vitamin K for the treatment of warfarin-associated coagulopathy. Ann Intern Med. 2002;137:251-4.
18. Harrell CC, Kline SS. Oral vitamin KI: an option to reduce warfarin's activity. Ann Pharmacother 1995;29:1228-32.
19. Crowther MA, Donovan D, Harrison L, McGinnis J, Ginsberg J. Low-dose oral vitamin K reliably reverses over-anticoagulation due to warfarin. Thromb Haemost 1998;79:1116-8.
20. Crowther MA, Julian J, McCarty D, Douketis J, Kovacs M, Biagoni L, et al. Treatment of warfarin-associated coagulopathy with oral vitamin K: a randomized clinical trial. Lancet 2000;356:1551-3.
21. Pengo V, Banzato A, Garelli E, Zasso A, Biasiolo A. Reversal of excessive effect of regular anticoagulation: low oral dose of phytonadione (vitamin K1) compared with warfarin discontinuation. Blood Coag Fibrinol 1993;4:739-41.
22. Weibert RT, Le DT, Kayser SR, Rapaport SI. Correction of excessive anticoagulation with low-dose oral vitamin K. Ann Intern Med 1997;126:959-62.
23. Patel RJ, Witt DM, Saseen JJ, Tillman DJ, Wilkinson DS. Randomized, placebo-controlled trial of oral phytonadione for excessive anticoagulation. Pharmacotherapy 2000;20:1159-66.
24. Lubetsky A, Yonath H, Olchovsky D, Loebstein R, Halkin H, Ezra D. Comparison of oral vs intravenous phytonadione (vitamin K1) in patients with excessive anticoagulation: a prospective randomized controlled study. Arch Intern Med 2003;163:2469-73.
25. Ageno W, Crowther MA, Steidl L, Ultori C, Mera V, Dentali F, et al. Low dose oral vitamin K to reverse acenocoumarol-induced coagulopathy: a randomised controlled trial. Thromb Haemost 2002;88:48-51
26. Fondevila CG, Grosso SH, Santarelli MT, Pinto MD. Reversal of excessive oral anticoagulation with a low oral dose of vitamin K1 compared with acenocoumarine discontinuation. A prospective, randomized, open study. Blood Coagul Fibrinolysis 2001;12:9-16.
27. Poli D, Antonucci E, Lombardi A, Gensini GF, Abbate R, Prisco D. Safety and effectiveness of low dose, oral vitamin K administration in asymptomatic outpatients on warfarin or acenocoumarol with excessive anticoagulation. Haematologica 2003;88:237-8.